| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de020b7dcbcaf745ca743fa95fa94853 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F13-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 |
| filingDate |
2019-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91f6cd2203ba9878f24953b0ab5083fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaa171b94179321f6252410c8f83eef6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ca61cbf3420c7dd22e808c3b4b3234e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91444178b7d6d3f0f2e3fd3f86c715a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cf39bf2525f235f4b87737701a8a2ae |
| publicationDate |
2020-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111138500-A |
| titleOfInvention |
Monoiodobenzoic acid-modified Anderson polyacid organic derivative A2 and its application in anti-EV71 virus |
| abstract |
The invention provides a monoiodobenzoic acid modified Anderson polyacid organic derivative A2 and its application in anti-EV71 virus. Through the research experiments on the EV71 virus inhibitory activity of the polyiodocarboxylic acid-modified Anderson polyacid organic derivative A1-A3, it was confirmed that the polyiodocarboxylic acid-modified Anderson polyacid organic derivative A2 could inhibit the cytopathic effect caused by EV71 virus. effect, enhance the survival rate of infected cells, and inhibit the replication and proliferation of EV71 virus in cells. The polyiodocarboxylic acid-modified Anderson polyacid organic derivative A2 provided by the present invention has the potential to prepare a specific therapeutic drug against EV71 infection, and has the advantages of good clinical application prospects. |
| priorityDate |
2019-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |